anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Accelerated biological aging has been verified to be a critical risk factor for a number of age-related diseases, but its role in dementia remained unclear. Whether it modified the effects of genetic factors was also unknown. This study evaluated the associations between accelerated biological aging and dementia and the moderating role of accelerated biological aging in the genetic susceptibility to the disease.
METHODS: We included 200,731 participants in the UK biobank. Nine clinical blood biomarkers and chronological age were used to calculate Phenotypic age acceleration (PhenoAgeAccel), which is a novel indicator for accelerated biological aging. The associations of PhenoAgeAccel with dementia, both young-onset and late-onset dementia, were assessed by Cox proportional hazard models. Apolipoprotein E (APOE) alleles and polygenic risk scores (PRS) were used to evaluate the genetic risk of dementia. The interactions between genetic susceptibility and biological aging were tested on both multiplicative and additive scales.
RESULTS: These findings showed individuals who were in the highest quartile of PhenoAgeAccel had a higher risk with incidence of dementia compared to individuals in the lowest quartile of PhenoAgeAccel (HR: 1.145 (95% CI: 1.050, 1.249)). Individuals with biologically older had a higher risk of dementia than individuals with biologically younger (HR: 1.069 (95% CI: 1.004, 1.138)). Furthermore, compared to individuals with biologically younger and low APOE ε4-related genetic risk, individuals with biologically younger and high APOE ε4-related genetic risk (HR:3.048 (95% CI: 2.811, 3.305)) had a higher risk of dementia than individuals with biologically older and high APOE ε4-related genetic risk (HR: 2.765 (95% CI: 2.523, 3.029)). Meanwhile, referring to low dementia PRS and biologically younger, the risk of dementia increased by 72.7% (HR: 1.727 (95% CI: 1.538, 1.939) in the biologically younger and high PRS group and 58.7% (HR: 1.587 (95% CI: 1.404, 1.793) in the biologically older and high PRS group, respectively. The negative interactions between PhenoAgeAccel with APOE ε4 and PRS were also tested on the additive scale.
CONCLUSIONS: Accelerated biological aging could bring the extra risk of dementia but attenuate the effects of genetic risk on dementia. These findings provide insights for precise prevention and intervention of dementia.
Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer that has been on the rise in recent times, particularly among older individuals. Cornulin (CRNN) is increasingly recognized as an oncogene involved in developing various types of tumors. However, the precise contribution to cSCC remains unclear. Our study observed a significant increase in CRNN expression in cSCC samples compared to healthy skin. CRNN expression in the SCL-1 cell line derived from cSCC was reduced, leading to a halt in cell growth during the transition from the G1 phase to the S phase. This reduction inhibits cell division, promotes cell death, and decreases cell invasion and migration. CRNN overexpression has been found to enhance cell growth and prevent cells from undergoing natural cell death, and the cancer-promoting effects of CRNN are linked to AKT activation. Using a mouse xenograft model, we demonstrated that the inhibition of CRNN led to a decline in cSCC tumor growth in a living organism, providing evidence of CRNN's involvement in cSCC occurrence and development. This study establishes a foundation for evaluating the effectiveness of CRNN in treating cSCC, enabling further investigation in this area.
Patients will be randomized to which side of the face will be injected with onabotulinumtoxinA and incobotulinumtoxinA. A total dose of 22.5 units of onabotulinumtoxinA and 22.5 units of incobotulinumtoxinA will be administered at baseline to the respected side of the face. One vial (100 MU) of BoNTA will be reconstituted with 2.0 mL of 0.9% sterile saline solution. Similarly, one vial (100 MU) of BTXCo will be reconstituted with 2.0 mL of 0.9% sterile saline solution. 2.5 units of the respective neurotoxin will be administered to three sites in the crow's feet area on each side (7.5 units total for one side), 2.5 units to two locations of the forehead on each side (5 units total for one side), and 5.0 units to two locations in the glabella on each side(10 units total for one side). The duration of the study will be 4 months. The followup visits after the initial injections will be at 3 days, 2 weeks, 3 months, and 4 months after the initial treatment. At each of these visits, standardized digital photographs of the treated facial area will be taken. Both static and dynamic photos will be taken of each region. At the conclusion of the study, three independent raters will individually perform blind assessments of the photographs according to the Validated Assessment Scaled for the Upper Face published by Flynn et al 2012.
PURPOSE:To obtain a sealing bag for a bathing agent capable of rapidly and uniformly diffusing the bathing agent into bath hot water and dissolving the bathing agent while producing a comfortable sound without floating partially undissolved water-soluble sealing bag on the hot water surface, by wrapping a foamable bathing agent in a water-soluble sealing bag. CONSTITUTION:A sealing bag for a bathing agent obtained by wrapping a foamable bathing agent in a water-soluble sealing bag. A material consisting essentially of polyvinyl alcohol, carboxymethyl cellulose, 4,4,6-tri-glu copolysaccharide, etc., is cited as the material for the water-soluble sealing bag and may contain a colorant, odorant, etc. The film thickness is 10-80mu. If the 4,4,6-tri-glucopolysaccharide is particularly used, dissolution and mechani cal characteristics are excellent and water-insoluble printing can be carried out on the surface, the dissolution characteristics can be readily regulated by adjusting the film thickness. Furthermore, pasteboard, e.g. polyester, etc., can be applied to a water-soluble film to increase the processing strength in filling the bathing agent.
PURPOSE:To obtain an antigen component of bovine leukemia vaccine sufficiently keeping the function as an antigen, by inactivating bovine leukemia virus (BLV) of crude protein containing BLV and subjecting to ultrafiltration. CONSTITUTION:A crude protein containing BLV is separated from a host cell infected with BLV or a cultured liquid of the cell. The BLV of the protein is inactivated with an inactivation agent (e.g. formalin or glutaraldehyde) and the obtained solution containing inactivated BLV is treated by ultrafiltration to remove a cell-originated component having a mol. wt. of <=10,000 and components such as inactivation agent and to obtain a concentrated fraction containing a protein useful as an antigen component of bovine leukemia vaccine. As an alternative method, the crude protein containing BLV is made to contact with a surfactant to effect the dissociation of the protein, separating a fraction containing core protein of BLV from the obtained mixture by ion exchange method and fractionating a fraction containing an envelope protein of BLV from the mixture free from said core protein by gel-filtration.
Cardiac dysfunction among cirrhotic patients has long been recognized in the medical community. While it was originally believed to be a direct result of alcohol toxicity, in the last 30 years cirrhotic cardiomyopathy (CCM) has been described as a syndrome characterized by chronic cardiac dysfunction in cirrhotic patients in the absence of known cardiac disease, regardless of the etiology of cirrhosis. CCM occurs in about 60% of patients with cirrhosis and plays a critical role in disease progression and treatment outcomes. Due to its predominantly asymptomatic course, diagnosing CCM is challenging and requires a high index of suspicion and a multiparametric approach. Patients with CCM usually present with the following triad: impaired myocardial contractile response to exercise, inadequate ventricular relaxation, and electrophysiological abnormalities (notably prolonged QT interval). In recent years, research in this area has grown expeditiously and a new set of diagnostic criteria has been developed by the Cirrhotic Cardiomyopathy Consortium, to properly identify patients with CCM. Nevertheless, CCM is still largely unknown among clinicians, and a major part of its pathophysiology and treatment is yet to be understood. In the present work, we aim to compile and summarize the available data on the pathogenesis, clinical features, diagnosis, treatment, and prognosis of CCM.
Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions. Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions. The invention relates to formulations for palatable foams with enhanced stability. In certain embodiments, the formulations include a base liquid (such as milk), a surfactant, a polysaccharide, and a polymer capable of molecular interaction with the polysaccharide. The formulations are versatile and can be adapted to create foams of various fat content, textures, and foam stabilities. The foams can be created with simple aeration systems such as disposable, pressurized canisters, as well as high-speed, bulk dispensation systems that are currently used in high turnover restaurants and convenience stores.
Genetic white matter disorders (leukodystrophies) are estimated to have an incidence of 1:5000 live births. As many as 50% of patients with white matter disease remain undiagnosed after conventional neuroimaging, biochemical and genetic testing, and therefore have unclassified leukodystrophies. Moreover, the mechanisms of disease in many leukodystrophies of known cause are very poorly understood: many are systemic abnormalities that manifest only in white matter. The purpose of this study is to: (a) define novel homogeneous groups of patients with leukodystrophy and work toward finding the cause of these disorders and (b) establish disease mechanisms in selected classified leukodystrophies. In order to achieve these goals, patients with leukodystrophy will be analyzed by clinical, neurophysiological, biochemical and genetic means. For goal (a), patients would have been diagnosed as having an unclassified leukodystrophy or no known cause of their leukodystrophy at outside centers. At the Clinical Center, such patients will undergo a series of neuropsychological, blood, urine, spinal fluid, radiological, and peripheral tissue pathological tests. Some of these tests will be part of a standard battery while others will be tailored to individual patients. For goal (b), selected leukodystrophies with a defined genetic cause will be selected for further mechanistic study, using clinical and laboratory tools to establish increased understanding of the underlying pathophysiology. It is hoped that the present study will help clarify the nosology of the leukodystrophies and significantly advance our understanding of the pathogenesis of these diseases.
The invention provides a rheumatism bone-curing medicine and its preparation method. The rheumatism bone-curing medicine is prepared from the following traditional Chinese medicinal materials: 100-400 g of Strychnos nuxvomica, 10-80 g of whole worm, 10-80 g of white batryticated silkworm, 10-80 g of ephedra stem, 10-80 g of cyathula root, 10-80 g of rhizoma atractylodis, 10-80 g of licorice, 10-80 g of clematis root, 10-80 g of frankincense, 10-80 g of myrrh and 10-80 g of long-noded pit viper. The rheumatism bone-curing medicine is prepared from pure traditional Chinese medicines. Compatibility between monarch and ministerial drugs is scientific and reasonable. Raw materials are rich. The medicine provided by the invention has no toxic or side effect and has effects of reducing dampness, relieving pain and strengthening tendons and bones.
Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
BACKGROUND: Severe and treatment-resistant pain is a major issue for patients with cancer. Cordotomy is an effective approach for addressing severe cancer-related pain. It is based on blocking the transmission of pain by damaging the lateral spinothalamic tract.
METHODS: Computed tomography guided cordotomy was performed on 14 patients who did not respond to medical and interventional pain management methods.
RESULTS: Fourteen patients with cancer pain underwent CT-guided percutaneous cordotomy. Pain relief was reported in 86% of the patients. The visual analog scale values before and after cordotomy were compared and a significant difference was found (p = 0.0001). The improvement in the Karnofsky Performance Scale score of the patients was found to be statistically significant (p = 0.0001).
CONCLUSION: We believe that CT-guided cordotomy, performed by experienced hands in a team of experienced individuals and applied to the right patients, is an effective treatment. However, it is crucial to exercise extreme caution regarding potential side effects and serious complications during the cordotomy procedure.
BACKGROUND: Negative emotions and insomnia (NEI) can lead to inflammation, which is a characteristic of sepsis. However, the interaction among NEI and sepsis has not yet been proven. Therefore, Mendelian mediation was used to explore this relationship in this study.
METHODS: The genetic correlation NEI and sepsis was assessed by via linkage disequilibrium scores (LDSC). A two-sample Mendelian randomization (MR) study design was performed to examine the causal association between NEI and sepsis using the inverse variance weighted (IVW) method. The reliability of the results was estimated by weighted median and MR-Egger methods, but heterogeneity was evaluated via Radial and Cochran's Q tests. Biases in gene polymorphisms were checked by MR-Egger regression and MR-PRESSO. Mendelian mediation analyses were applied to quantify the intermediary effect and proportional contribution.
RESULTS: A genetic link between sepsis and depression was determined via LDSC analysis. The relationship between depression and sepsis was revealed through MR analysis [odds ratio (OR) = 1.21, 95 % confidence interval (CI) = 1.08-1.36, p = 1.07 × 10-3)]. The results were not influenced by heterogeneity or pleiotropy biases. Chitinase 3 Like 1 (CHI3L1) was a mediator with a mediation effect size of 0.12. The ratio of the intermediated effect to total effect was 10.31 %.
CONCLUSION: CHI3L1 is a key factor which mediates the interaction between NEI and sepsis.
Stem cells have gained attention as a promising therapeutic approach for damaged myocardium, and there have been efforts to develop a protocol for regenerating cardiomyocytes (CMs). Certain cells have showed a greater aptitude for yielding beating CMs, such as induced pluripotent stem cells, embryonic stem cells, adipose-derived stromal vascular fraction cells and extended pluripotent stem cells. The approach for generating CMs from stem cells differs across studies, although there is evidence that Wnt signaling, chemical additives, electrical stimulation, co-culture, biomaterials and transcription factors triggers CM differentiation. Upregulation of Gata4, Mef2c and Tbx5 transcription factors has been correlated with successfully induced CMs, although Mef2c may potentially play a more prominent role in the generation of the beating phenotype, specifically. Regenerative research provides a possible candidate for cardiac repair; however, it is important to identify factors that influence their differentiation. Altogether, the spontaneously beating CMs would be monumental for regenerative research for cardiac repair.
Milk or whey, before or after a fermentation by lactic bacteria, is mixed with 8-18C n-fatty alcohols and the mixture sulphonated. The product is pref. partly or completely neutralised after sulphonation and natural or synthetic aromatic substances, plant extracts or colours added. The milk or whey may be saponified by bacterial conversion of fatty alcohols. Cleansing efficiency of the products, which are suitable for cleaning and care of the skin, is better than that of conventional alkali soaps. Their low pH (5-6) exerts a protective effect on skin acids. They are suitable for babies and people subject to detergent allergies.
Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
The invention concerns the phosphoryl-transporter protein 10 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemophathy, infection of HIV, immunological diseases and a variety of inflammations utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes the phosphoryl-transporter protein 10.
A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - "I want to do everything I can to prevent HIV," privacy - "I don't want others to know about the exposure," or cost - "I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making.
The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD oral/enteral Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR \>= 60 mL/min/1.73m2) oral/enteral Nirmatrelvir. Investigators are advised to consider withholding treatment if the participant's eGFR \< 30 mL/min/1.73m2.
Embodiments herein include medical systems, devices, and methods for assessing the health status of a patient. In an embodiment, a method includes evaluating the presence of volatile organic compounds in a breath or gas sample of the patient with a plurality of graphene sensors to generate volatile organic compound data, wherein the plurality of graphene sensors include sensors that are specific for different volatile organic compounds. The method can further include collecting data regarding the patient's sympathetic nervous activity. The method can further include combining the volatile organic compound data with the collected data regarding the patient's sympathetic nervous activity to form a combined data set. The method can further include matching the combined data set against one or more data patterns to find the best match, the best match indicating the health status of the patient. Other embodiments are also included herein.
The present invention discloses a medicine for relieving coughs and asthma, which is prepared from ephedra, apricot kernel, dried old orange peel, poppy shell, bulbus fritilariae, alum, liquoric root, carbetapentane citrate, prednisone, clenbuterol and chlortrimeton. The medicine adopts a combined prescription of traditional Chinese medicine and western medicine, treats both manifestations and root cause of diseases and has the functions of resisting sepsis, relieving inflammation, improving pulmonary circulation, enhancing immunological function of human bodies, etc. The medicine has obvious therapeutic effects on bronchial asthma, trachitis, pneumonectasis, pulmonary heart diseases, etc. and the advantages of obvious effect, good therapeutic effect, high cure rate, safety, reliability, etc. The cure rate reaches 68%, and the effective rate reaches more than 96% without toxic or side effect and untoward reactions. The medicine also has the advantages of simple preparation method, low price, easy popularization and wide application prospect.
Sesame oil was applied by the researcher to the patients assigned to the intervention group. Sesame oil was applied to the 10 cm circumference of the cannula, in the form of 10 drops and 10 minutes.
PURPOSE: A nanocomposite for reconstruction or regeneration of chondrocytes and a method for differentiating stem cells into chondrocytes are provided to effectively deliver hSOX9 gene and siRNA to mesenchymal stem cells. CONSTITUTION: A nanocomposite for reconstruction or regeneration of chondrocytes is prepared by binding hSOX9 gene or nucleotide siRNA containing a base sequence of sequence numbers 1-6 on nanoparticles of biodegradable polymers. The biodegradable polymers are a poly(lactic-co-glycolic acid). The weight ratio of the hSOX9 gene and biodegradable polymers is 1:40-100. A method for differentiating mesenchymal stem cells into chondrocytes comprises a step of culturing the mesenchymal stem cells under the presence of the nanocomosite. A pharmaceutical composition for reconstruction or regeneration of chondrocytes contains the nanocomposite-introduced mesenchymal stem cells and pharmaceutically acceptable carrier.
OBJECTIVE: To investigate predictors of surgical success for patients undergoing robotic ureteral reconstruction (RUR) for ureteropelvic junction obstruction (UPJO), proximal, and middle ureteral stricture disease.
METHODS: We retrospectively reviewed our multi-institutional Collaborative of Reconstructive Robotic Ureteral Surgery database to identify all consecutive patients undergoing RUR for UPJO, proximal and/or middle ureteral stricture disease between April 2012 and December 2020. The specific reconstruction technique was determined by the primary surgeon based on clinical history and intraoperative findings. Patients were grouped according to whether they were surgical successful. Preoperative variables between both groups were compared using chi-square tests. All independent variables with associations of P <.2 then underwent a binary logistic regression analysis to determine predictive variables of success for RUR (P ≤.05 was considered statistically significant).
RESULTS: Overall, 338 patients met inclusion criteria. Surgical success rates of RUR are shown in Table 1. Univariate analysis (Table 2) showed that there were a lower proportion of patients with diabetes (8.9% vs 25.7%, P <.01) and a higher proportion of patients who underwent ureteral rest (74.3% vs 48.6%, P <.01) in the surgical success group. Multivariate logistic regression analysis (Table 3) further revealed the odds of surgical success in patients without diabetes was 3.08 times ((confidence interval) CI 1.26-7.54, P = .01) the odds of success for patients with diabetes. The odds of surgical success in patients who underwent preoperative ureteral rest were 2.8 times (CI 1.35-5.83, P = .01) the odds of success for patients who did not undergo preoperative ureteral rest.
CONCLUSION: Surgical success of RUR for management of UPJO, proximal, and middle ureteral strictures may be influenced by factors including preoperative ureteral rest and presence of diabetes.